The first step is taking your comprehensive health assessment which includes a detailed look at your lab work results, BMI calculation, cognitive health evaluation, and a 30-minuts consultation with a clinician
H., Ozeki, M., Juneja, L
Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2
doi:10.7570/jomes21071 Fletcher MM, Keov P, Truong TT, et al
Wegovy should only be used under the guidance of a registered healthcare professional
Side Effects and Safety Considerations While generally well-tolerated, Semaglutide may cause side effects such as nausea, vomiting, and diarrhea, particularly during the initial stages of treatment